CVS Health (CVS) stock is spiraling Friday after the pharmacy chain and health benefits provider announced the appointment of a new CEO.
Effective October 17, David Joyner took over as president and CEO of CVS Health, replacing Karen Lynch, who had been in the position since February 2021. Joyner has 37 years of experience in the healthcare and pharmacy benefit management industries, most recently serving as executive vice president of CVS Health and president of CVS Caremark.
"There is no greater honor than to lead a company whose mission and purpose are completely focused on improving health," Joyner said in a statement. "I came back to CVS Health in 2023 because I believed I could give more to the company, and I take this opportunity today for the same reason. I am proud to continue working side by side with our 300,000 colleagues who are building a world of health around every consumer."
Sign up for Kiplinger’s Free E-Newsletters
Profit and prosper with the best of expert advice on investing, taxes, retirement, personal finance and more - straight to your e-mail.
Profit and prosper with the best of expert advice - straight to your e-mail.
The news comes less than three weeks after reports surfaced that CVS was conducting a strategic review of its business and had hired bankers to assist in exploring options, including a possible breakup of its retail and insurance units.
CVS Health's preliminary Q3 results fall short
In the press release, CVS also provided preliminary guidance for its third quarter, calling for earnings per share in the range of $1.05 to $1.10.
The forecast falls well below analysts' expectations for third-quarter earnings of $1.70 per share, according to Yahoo Finance.
"In light of continued elevated medical cost pressures in the Health Care Benefits segment, investors should no longer rely on the Company's previous guidance provided on its second-quarter 2024 earnings call on August 7, 2024," CVS added.
Is CVS stock a buy, sell or hold?
CVS Health has had a rough year on the price charts, as well. Shares have fallen more than 26% since the start of 2024, but Wall Street remains bullish on the healthcare stock.
According to S&P Global Market Intelligence, the average analyst target price for CVS is $70.10, representing implied upside of 20% to current levels. Additionally, the consensus recommendation is Buy.
Financial services firm Argus Research is one of those with a Buy rating the large-cap stock and a $75 price target.
The shares trade at an attractive valuation and CVS boasts a healthy 4.2% dividend yield which seems sustainable, wrote Argus Research analyst Christopher Graja in an October 2 note. However, the analyst admitted that he's "disappointed with the recent performance of the Health Care Benefits business" and is "not sure that our Buy recommendation can withstand another guidance cut or a deterioration in credit-quality metrics."
Related content
-
Why Now Is the Best Time To Protect Yourself From Potential FraudYou can implement these easy measures today to reduce the risk of financial harm from exposed data.
-
Three Creative Ways to Lower Your Retirement TaxesTax Tips You can apply key minimalism concepts for potential tax savings. Here’s how.
-
Netflix Stock Jumps to the Top of the S&P 500 After Earnings. Here's WhyNetflix stock is spiking Friday after the streaming giant beat third-quarter expectations and gave an upbeat fourth-quarter outlook.
-
Should You Move Your 401(k) to an IRA Once You Hit 59½?Some 401(k)s allow for in-service withdrawals at age 59½, opening up greater investment options. Here are three reasons for taking the plunge.
-
When It Comes to Insurance, How Much Risk Can You Take?Either you or an insurance company takes on the risk of protecting your belongings from loss or damage. Can you afford to self-insure?
-
Stock Market Today: Dow Gains on Strong September Retail SalesTaiwan Semiconductor Manufacturing's earnings beat and solid outlook created tailwinds for several chip stocks.
-
Elevance Health Stock Sinks as Medicaid Woes Hit EarningsElevance Health stock is plunging Thursday after the insurer missed Q3 earnings expectations and lowered its full-year outlook. Here's what you need to know.
-
Why Lucid Group Stock Is Plunging TodayLucid Group stock is spiraling Thursday after the EV maker said it is selling stock to raise cash. Here's why that's important to investors.
-
Taiwan Semiconductor Stock Hits a $1 Trillion Market Cap After EarningsTaiwan Semiconductor stock is red-hot in Thursday's session after the chipmaker beat Q3 expectations and issued a strong outlook. Here's what you need to know.
-
Five Ways to Minimize a Higher Capital Gains Tax RateWith Harris’ proposal to raise the capital gains tax rate (which would require congressional approval), investors might want to consider tax-lowering options.
